The Stanford Chronic Care Management System


Information for Pharmaceutical Companies

The Stanford system has demonstrated clearly that many patients who were recently discharged from hospitals are taking duplicate medications, and/or omitting prescribed medications. This occurs either because of the lack of coordination between the hospital and the outpatient clinic, or because of lack of effective communication between the prescribing physician and the patient.

The result of duplicates and omission is a significant reduction in the efficacy of pharmacotherapy, which detracts from the reputation of the pharmaceutical manufacturer and the medication itself.

If pharmacotherapy is to play a more prominent role in the treatment of coronary artery disease compared with surgical and other interventional techniques, it is vital that the infrastructure that supports the effectiveness of pharmacotherapy be strengthened. SCCMS is one of the most effective means for doing so.

In fact, pharmaceutical companies have a major stake in assuring that the medications prescribed by physicians are taken by patients in the manner prescribed, and over an extended period. As a result, these companies have invested substantially in methods for enhancing compliance with pharmacotherapy, including support of the care management approach that is incorporated into SCCMS. The database system built into the SCCMS, and the periodic telephone contacts initiated by the nurse care manager, help to assure that actual pharmacotherapy is consistent with prescribed pharmacotherapy, and that any side effects or other untoward effects are addressed promptly.

Use of the SCCMS thus provides a significant and highly cost effective benefit to the pharmaceutical industry.